Navigation Links
Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD
Date:5/25/2010

NEW ORLEANS, May 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years.  The data, presented in an oral session at a national scientific meeting of psychiatrists in New Orleans, LA, demonstrated that treatment with Vyvanse (30, 50, and 70 mg/d) significantly improved ADHD symptoms compared to placebo in adolescents with ADHD.

Vyvanse is currently indicated for the treatment of ADHD in children aged 6 to 12 years and in adults.  Recently, Shire submitted a supplemental New Drug Application (sNDA) for use of Vyvanse in the treatment
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... The Oklahoma tornado left the state ... mayor of Moore, one of the heavily damaged towns, proposed ... from cnn.com. Reaching out to also be of help, My ... Shield to counter the looming mold problem. , The ... 2013, caused 24 deaths, My Cleaning Products shared. Ten of ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Quincy ... discovery and development of calcium-binding proteins to support ... safety assessment study of apoaequorin in ... journal published for the British Industrial Biological Research ... was to investigate potential adverse effects, if any, ...
(Date:5/23/2013)... Every day, their baby stopped breathing, his collapsed bronchus ... April and Bryan Gionfriddo watched helplessly, just praying that ... few doctors said he had a good chance of ... her now 20-month-old son, Kaiba. "At that point, we ... it and run with it." , They found hope ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
Breaking Biology Technology:Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3
... 2011 NeoStem, Inc. (NYSE Amex: NBS ) ... focus on cell-based therapeutic development, today announced that the Company ... Wednesday evening, August 24, 2011. The segment focused ... adult stem cells for first responders, the nuclear industry, the ...
... Calif., Aug. 25, 2011 Emmy® and Tony® award-winning ... ) today launch Act 2 Reduce Fractures™, an educational ... for fractures. Earlier this year, Danner was diagnosed with ... to encourage women like her to educate themselves, take ...
... New Leaf Venture Partners (NLV Partners) have contested the terms of ... (NYSE: PFE ) in a letter filed today with ... plans to purchase the shares of Icagen stock it already does ... an aggregate transaction value of approximately $56 million.  In the past ...
Cached Biology Technology:Stem Cell Treatments for First Responders in the News 2Stem Cell Treatments for First Responders in the News 3Stem Cell Treatments for First Responders in the News 4Stem Cell Treatments for First Responders in the News 5Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 2Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 3Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 4Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 5Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 6Award-Winning Actress Blythe Danner and Amgen Launch Act 2 Reduce Fractures™ Educational Campaign 7Merlin Nexus and New Leaf Venture Partners Continue to Contest Proposed $56 Million Acquisition of Icagen by Pfizer 2Merlin Nexus and New Leaf Venture Partners Continue to Contest Proposed $56 Million Acquisition of Icagen by Pfizer 3
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/23/2013)... MADISON, Wis. In an age when microbial pathogens ... to tamp down infection, a team of Wisconsin scientists ... of curbing the bacteria that cause staph infections. , ... Chemical Society , a group led by University of ... interfere with the "quorum sensing" behavior of Staphylococcus ...
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2University of Wisconsin chemists find new compounds to curb staph infection 2Detecting mirror molecules 2Detecting mirror molecules 3
... at a number, letter or other shape, neurons in ... different components of that shape, almost instantaneously fitting them ... the individual then "sees" and understands, researchers at The ... university's Zanvyl Krieger Mind/Brain Institute describes the complex but ...
... tracking of new drugs for commercial licensing are raised by ... approval of natalizumab, a new drug for multiple sclerosis, and ... a life threatening condition while being treated. , Natalizumab was ... for use in relapsing multiple sclerosis on the basis of ...
... of a fundamentally new "candidate," or potential, vaccine for ... people annually, is reported in the current issue of ... of infected female sand flies, visceral leishmaniasis infects about ... in India, Bangladesh, Nepal, Sudan and Brazil. , Despite ...
Cached Biology News:In the mind's eye: How the brain makes a whole out of parts 2Potential vaccine developed for deadly leishmaniasis disease 2Potential vaccine developed for deadly leishmaniasis disease 3
... to meet your laboratory's requirements for data management and quality control. ... ... ... is the standard software for Staccato Systems and custom Allegro Modules allowing for the simple interface ...
... This microscope is described by end-users to ... incorporates the fundamentals of light microscopy and ... small footprint, it does not require much ... a busy lab environment. The DM-BA300 combines ...
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
... Life Science LAS-3000mini is a compact ... chemiluminescence applications, and the perfect standard ... 's LAS-3000 provides significantly improved system ... Glowell calibration standards validate that Fujis ...
Biology Products: